Theravance Biopharma reports record Q4 and full year 2024 financial results with YUPELRI and TRELEGY milestones

Theravance Biopharma, Inc.

2024-FY EPS reported -$1.15 revenue$64,381,000

YUPELRI US net sales reached $66.7M in Q4 2024 and $238.6M for full year, up 10% and 8% year-over-year, driven by increased customer demand.
TRELEGY global net sales of $3.46B in FY 2024 triggered a $50M milestone from Royalty Pharma, received in February 2025.
Company ended Q4 2024 with $88M cash, and CYPRESS study on track to enroll final patient by mid-2025.
Q4 2024 total revenue was $18.8M from Viatris collaboration, with net loss of $15.5M and non-GAAP net loss of $2.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.